fig1
![Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer](https://image.oaes.cc/34416d25-f853-460b-a741-e4b4208554a9/4770.fig.1.jpg)
Figure 1. Schematic representation of major DNA repair pathways[8]. PMS2: postmeiotic segregation increased 2, MLH1: mutL homolog 1, ERCC1/4: Excision repair cross-complementing 1/4, RAD51: RAD51 recombinase, FANC: Fanconi anaemia complementation group, BRCA1/2 : Breast cancer gene 1/2, DNAPKs: DNA protein kinases, PARP1: Poly (ADP-ribose) polymerase, XRCC5/6: X-Ray Repair Cross Complementing 5/6, ATM: ATM Serine/Threonine Kinase, ATR: Ataxia telangiectasia and Rad3-related, CHK1: checkpoint kinase 1, HR: homologous recombination, NHEJ: non-homologous end joining.